DNA Supplement Gap

Where nutrigenomic marketing claims outrun the published evidence

Current Stage

—

Genes Marketed

—

Avg Effect Size (R²)

—

Claims Past Bar

—

Evidence Grade

—

Panel Size (Genes Sold)20

Evidence Bar — Min. R²2.0%

Marketed gene / supplement claim

Raw SNP genotype call

Weak / below-bar evidence

Unexplained variance / polygenic background

FTC / FDA enforcement action